Retatrutide: A Novel Triple Agonist Delivering Unprecedented Weight Loss
The First Triple Agonist for Antiobesity: Retatrutide.
Abstract
The First Triple Agonist for Antiobesity: Retatrutide.
Authors: Tetelbaun L, Mullally JA, Frishman WH
Journal: Cardiology in review (2024)
DOI: 10.1097/CRD.0000000000000793